Adele Gulfo has served as chief executive officer of the Biopharma Commercial Unit at Sumitomo Pharma America since the Company’s formation in 2023, with oversight of the Company’s commercial products APTIOM®, GEMTESA®, LATUDA®, MYFEMBREE®, ORGOVYX®, and RETHYMIC®.
Previously, she served as chief commercial and business development officer at Sumitovant Biopharma from 2020 to 2023. From 2018 to 2019, she served as chief commercial development officer at Roivant Sciences, where she was influential in the formation of Sumitovant and in preparations for the launches of ORGOVYX® (prostate cancer) and MYFEMBREE (women’s health).
From 2014 to 2018, Adele served as executive vice president and chief strategy officer at Mylan N.V. (now Viatris), where she led the expansion into new geographies and the development and growth of the company’s global specialty pharmaceutical franchise. Before joining Mylan, Adele spent five years at Pfizer in positions of increasing responsibility, including president and general manager of Pfizer’s $12B+ U.S. primary care business unit, as well as country manager for Pfizer's U.S. Biopharma business, including specialty and oncology business units. Earlier in her career at Pfizer, Adele was instrumental in the development, launch, and commercial success of LIPITOR, which became the world’s best-selling medicine. Prior to Pfizer, Adele held vice president roles within AstraZeneca, including leading business development/innovation and design for launch brands, as well as the multi-billion-dollar cardiovascular business unit. She oversaw the launch of Crestor® and its growth into a $2 billion medicine.
Adele received a BS in biology and chemistry and an MBA in marketing from Seton Hall University. She also holds an MBA with highest honors from Fairleigh Dickinson University and trained in post-graduate molecular biology at the University of Medicine and Dentistry of New Jersey.